Heineken flags GLP‑1 risk to UK beer sales

Heineken has warned British pubs and bars that the growing use of GLP‑1 weight‑loss drugs could lead to a fall in beer and cider sales. The brewer told UK hospitality customers that medicines such as Ozempic and Wegovy can reduce the desire to drink alcohol, raising the risk of fewer full‑pint servings and a decline in traditional multi‑pint drinking sessions.

In a presentation shared with British hospitality businesses, Heineken said the emerging GLP‑1 era may result in “fullness and fewer serves” in pubs and bars. The Netherlands‑headquartered group framed the briefing as part of its regular engagement with UK customers to help them understand evolving consumer habits.

Heineken said it is already observing changes in consumption behaviour among GLP‑1 users and plans to keep monitoring how these patterns develop in 2027. Identified trends include a shift towards smaller serves, lower‑alcohol drinks and more premium products.

The brewer noted that these shifts among GLP‑1 users are consistent with broader trends in the market, particularly among younger generations, who are already showing a preference for moderation and higher‑quality offerings. Surveys by research firms including Circana, NIQ and KAM have pointed to reduced drinking among GLP‑1 users.

Heineken’s warning comes against a backdrop of rapidly rising GLP‑1 use. JPMorgan said 10 million people in the US turned to medication for weight loss last year. Other analysis points to GLP‑1 households spending less on groceries, including alcohol and sugary drinks, and to lower overall food‑and‑beverage spending as users cut calories.

These trends reinforce concerns that wider adoption of GLP‑1 treatments could curb alcohol consumption and reduce on‑trade volumes in pubs and bars. Heineken has positioned its UK advisory efforts as a way to help venues navigate these shifts and limit potential declines in visits and spending.

To respond to changing habits, Heineken has urged pubs to adapt their offer. Suggested measures include promoting half pints instead of full pints, expanding low‑ and zero‑alcohol ranges, and pairing drinks with small plates of food to maintain engagement and spending even if alcohol volumes fall.

The company underlined the current structure of the British pub beer market, estimating almost £14bn in beer sales in pubs, bars and restaurants in the year to February. Less than £300m of that total came from no‑ and low‑alcohol products, indicating that alternatives to full‑strength beer still represent a small share of sales.

Other major drinks groups have offered different assessments of GLP‑1 risks. The Guinness maker, Diageo, has told investors that any impact from weight‑loss drugs becoming mainstream should be manageable. Carlsberg has said that data does not currently support the view that GLP‑1 use is affecting beer consumption trends.

Surveys by research companies have pointed to reduced drinking by GLP‑1 users.